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Background: From an ethical perspective, clinical research involv-
ing humans is only acceptable if it involves the potential for benefit. 
Various characteristics can be applied to differentiate research benefit. 
Often benefit is categorized in direct or indirect benefit, whereby indi-
rect benefit might be further differentiated in collective or benefit for 
the society, excluding or including the trial patient in the long term. 
Ethical guidelines, such as the Declaration of Helsinki in its latest 
version, do not precisely favor a particular type of benefit. However, 
to conceptualize clinical research benefits it is relevant to differentiate 
between the potential individual benefit or the social benefit expected 
from the study, either with or without a potential long term beneficial 
option for the individual trial participant.
Objectives: The narrative review was designed to screen related liter-
ature to identify the most occurring benefits which could be afforded 
by clinical research and to further detail the beneficial outcomes in 
order to learn about the characteristics values specifying individual 
and social benefits.
Methods: Literature on research benefit was identified by search-
ing PubMed database using several combinations of keywords like 
“benefit” and “clinical research” or “direct benefit” and “clinical 
research.” The search was limited to articles published in English 
language. Likewise, a google search with the same combinations 
of keywords was done. Additionally, the reference lists of instantly 
promising articles were screened for further thematically adapted 
articles.
Results: Based on the reviewed literature it can be stated that the 
principle of benefit from drug development is routinely divided into 
two main classes, namely individual benefits for the patients on one 
hand and into collective benefits for the society.1 Thirty-four of an 
overall 39 articles and publications by governmental medical insti-
tutes focused on the personal benefit of the patients. In this group 
the leading benefits were an increased quality of life (42.2%), access 
to health care and drugs (29.4%), up-to-date care (29.4%), feeling 
of altruism and helping future patients (17.6%), payments received 
(17.6%), and improvement of survival rate (14.7%). The collective 
benefit was discussed in 18 of the articles. The main benefits in this 
area were the general knowledge gain (72.2%), subsequent availabil-
ity of new treatments and drugs (27.8%), better access to medicines 
(11.1%), sustainability of health care (11.1%), and improvement of 
health care (11.1%).
Conclusions: Individual patient benefit from drug development 
appears to be more frequent than benefits concerning the society 
in general. Though a scientific approach is population based and 
consequently closer to the social benefit category, the data might not 
only be purely statistically evaluated. Each individual patient has the 
right to look and hope for a personal benefit from participating in a 
clinical trial without putting a feeling of pure altruism on top prior-
ity.2 From an ethical point of view each benefit achieved for individual 
patients as part of a clinical trial testing new treatments, drugs or 
medicinal products, might be seen as social benefit as well, and even 
more in case the tested drug or device will be made available for all 
patients of the country, where the clinical trial was conducted, after 
its’ market approval.3
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